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The S h o r t -A c t in g  B a r b i t u r a t e s  A s  
I n t r a v e n o u s  A n e s th e t ic s
By A. H. MALONEY, Ph.D., M. D., Washington, D. C.
IN 1875, Oré1 successfully employed chloral hydrate intravenously in the production 
of general anesthesia. Since that time vari­
ous other hypnotics, such as methyl-propyl­
carbinol-urethane (Hedonal), trichlorisopro- 
pyl alcohol (Isopral), isoamyl-ethyl (Amy­
tal), secondary-butyl-bromallyl (Pernoston), 
ethyl-1: methyl-butyl (Nembutal), and cyclo- 
hexenyl-ethyl (Phanodorn) barbituric acid, 
and even ether in Ringer’s solution have 
been employed.
The use of the barbiturates dates back 
only to 1929. It was in that year that 
Zerfas2 and his co-workers, at the Indiana 
University School of Medicine and Hos­
pitals, found that Sodium Amytal wTas capa­
ble of producing surgical anesthesia. How­
ever, it was soon found that this and the 
other barbiturates named above exhibited 
definite disadvantages when employed as 
general anesthetics. Patients subjected to 
them were prone to sleep unduly long post- 
operatively, and about 25 percent showed 
extreme hyperexcitability, either during in­
duction or following the operation. As a 
consequence, their use was restricted to the 
field of basal anesthesia.
In 1932, methyl-cyclohexenyl-methyl bar­
bituric acid (Evipan) was synthesized. Used 
as the sodium salt, this barbiturate quickly 
gained favor as a general anesthetic, first 
in Europe and later in America, for use in 
operations of short duration (15 to 20 min­
utes). It was characterized by the produc­
tion of rapid induction, good somatic and 
visceral relaxation, seldom an alarming fall 
of blood pressure, satisfactorily short post­
operative narcosis, and usually no post­
operative gastric disturbances. Patients 
who have been anesthetized with it have 
expressed satisfaction.
Following in the wake of Evipal, there 
have appeared sodium ethyl-1 :methyl-butyl- 
thio-barbiturate (Thio-Nembutal, or Pento- 
thal Sodium), sodium allyl secondary-butyl- 
thio-barbiturate (Thiosebutal) ,andl :methyl- 
(5-5) allyl-isopropyl barbiturate (Narco- 
numal). These compounds manifest a strik­
ing similarity of dynamic action, excepting 
the fact that Pentothal is approximately 
one-third more toxic than Evipal; and Thal- 
heimer3, who has used Narconumal more
than Evipal, prefers the former, claiming 
for it an absence of the factor of excite­
ment. Although I have used them all, I 
have had widest experience with Evipal and 
prefer it to the others solely on that ac­
count. My discussion will be confined to 
Evipal Soluble, though I would have it un­
derstood that whatever is said of Evipal 
applies equally as well to the other members 
of this particular group.
Discussion
Every anesthetic agent has its peculiar 
disadvantages and limitations. In the study 
of any therapeutic agent it is imperative to 
know its particular limitations and disad­
vantages. This is the best safeguard against 
bringing a good agent into disrepute. 
Among the limitations and disadvantages of 
this group of barbiturates, used for intra­
venous anesthesia, should be mentioned the 
following:
1.— Toxicity and Absorption: From the
results of an extensive experience with lab­
oratory animals, and a somewhat more lim­
ited clinical experience with Evipal, I have 
been able to make some interesting observa­
tions regarding the question of the toxicity 
of this compound. The problem of toxicity, 
within reasonable limits, is a function of the 
rate and mode of administration, rather 
than the size of the individual dose. This 
is due to the fact that absorption plays a 
more dominant role than the quantity ad­
ministered. Thus, when Evipal is given by 
mouth or subcutaneously, the rate of ab­
sorption may be so slow that detoxification 
within the system may run almost parallel 
with absorption. In this event the amount 
actually administered over a period of time 
could reach startling figures. As the equa­
tion shifts from the side of absorption, the 
end-point of an otherwise surely fatal dose 
might be expressed merely in terms of 
stupor, dizziness, or incoordination.
Two years ago, Maloney and Hertz4 re­
ported on this point as follows: “ The hazard 
of toxicity is inherent, not in the drug per 
se, but rather in its absorption constant in 
the system in any unit of time.” When 
administered intravenously, in which case 
absorption is immediate, Evipal presents a
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distinct problem in toxicity. If the rate is too 
rapid, it may produce sudden paralysis of 
the respiratory center, resulting in death or 
profound respiratory embarrassment.
2. —Anesthetic Inefficiency and Tissue
Damage: Under the caption of toxicity and 
absorption, the dangers at both extremes, 
incident to the rate of injection, were 
stressed. But here is another problem as­
sociated with slowness of injection rate. 
This problem is two-fold: (1) Failure to
produce anesthesia due to the fact that de­
toxification may run parallel to absorption. 
In this case the drug is likely to be blamed 
when, in fact, the anesthetist is at fault; 
and (2) the detoxifying mechanism may 
break under the severe strain of the large 
dose required and permanent liver damage 
result from an irreversible toxic cellular 
reaction.
3. —Non-volatility: Anesthetists and phar­
macologists are agreed on the point that 
an acceptable anesthetic is one that is easily 
controllable. By their very nature the vola­
tile anesthetics meet this criterion. Regard­
ing the barbiturates used for general anes­
thesia there are conflicting opinions. Without 
any pretentions at settling the question, I 
am prepared to state that picrotoxin, the 
most effective antidote for barbiturate in­
toxication, serves as a good control in Evipal 
anesthesia, both prophylactically and anti- 
dotally. I use picrotoxin prophylactically 
as a routine measure to protect the respira­
tory center from the paralyzing action of 
Evipal in an overdose.
Unsuitable Cases
Evipal is not suitable for every case. As 
with other anesthetic agents, a judicious 
selection is imperative, in which complicat­
ing factors and contraindications are to be 
recognized. On the question of complicating 
factors, Heard5 mentions early bronchiecta­
sis, diabetes, hypertension, endocarditis, and 
advanced carcinoma. Of course, this list, 
with the possible exception of hypertension, 
would constitute “ complicating factors” with 
virtually every sort of anesthetic. If care­
ful pre- and postoperative management of 
individual cases falling within these cate­
gories is exercised, there is no reason why 
Evipal could not with safety be employed. 
It is well tolerated in cases exhibiting hyper­
tension, provided there is no significant 
associated impairment of hepatic function. 
Two cases in our series (Maloney6), with 
hypertension, showed marked diminution of 
pressure (240 to 200, and 160 to 88 systolic).
The major contraindication to Evipal 
anesthesia is direct impairment of liver 
function or any morbid condition which 
would tax heavily the detoxifying capacity 
of the liver. I cannot stress too strongly 
the importance of hepatic dysfunction.
Evipal is almost wholly detoxified by the 
liver. If liver function is definitely im­
paired, a normal therapeutic dose of Evipal 
might prove fatal. Two cases in point have 
come to my attention: The first had a posi­
tive Fouchet test, indicative of hepatic dys­
function. In spite of this finding, Evipal 
was employed, contrary to routine instruc­
tions. The patient had a very stormy post­
operative experience. The second case was 
a patient with burns over a wide surface 
of his body. Evipal was given illadvisedly. 
The result was a fatal toxemia.
Duration of Anesthesia
Opinion is unanimous that Evipal makes 
an ideal anesthetic for operations of short 
duration. While I am in hearty accord, it 
is but fair to point out the triteness of this 
statement. It holds true for all anesthetics. 
My claim is that, with Evipal, shortness of 
duration of anesthesia is not definitive. 
Within reasonable limits (such as are 
allowed for any other anesthetic agent), it 
makes no difference how short or long a 
time the anesthesia under Evipal is to last. 
Safety of induction is the problem of first 
consideration. When once induction has 
been successfully obtained, duration becomes 
a matter of fractional injection, as required 
to maintain a given level of anesthesia with 
smoothness. Provided that the respiratory 
center is; given adequate protection by the 
prophylactic employment of picrotoxin, any 
ordinary operation may be performed, re­
gardless of time. I found, in our first series 
of 40 cases, that the average duration was 
58.85 minutes; 18 lasted 60 minutes or 
more; 3 lasted 125, 125, and 133 minutes, 
respectively.
Technic of Administration
The patient is prepared in the usual 
manner on the night preceding operation. 
Morphine, with scopolamine or atropine, 
may be given, if necessary, to insure psychic 
or nervous stability and an adequate amount 
of restful sleep. However, I would strongly 
urge that no sedative be given just before 
the anesthetic, because it complicates the 
general picture by potentiating the depres­
sant action of Evipal in a way that cannot 
be measured with accuracy, and thereby pre­
vents a correct estimation of the effective 
anesthetizing dose. Avoidance of these 
factors of danger is of greater importance 
than lessening the initial amount of the 
anesthetic agent.
Upon a signal of readiness from the sur­
geon, 1 to 2 cc. of a 0.3-percent solution of 
picrotoxin is injected intramuscularly. The 
patient is then asked to count audibly as 
soon as the needle delivering the Evipal so­
lution is in the vein and the injection started. 
The injection is made fairly rapidly until
the patient’s voice fades away. Undue 
slowness of the injection rate serves to in­
crease the induction time and the initial 
amount of the anesthetic required. In man, 
the injection rate must be more rapid than 
in laboratory animals, because of the rela­
tively longer course of the systemic circu­
lation in man. Using the same caliber 
syringe and needle at all times, the tech­
nician quickly learns to gauge the optimal 
rate of injection.
With the fading off of the patient’s voice, 
an additional one-third of the amount 
already delivered is then given. The ad­
ministration is now stopped, the needle 
being held in position in the vein for subse­
quent fractional injections. The signal is 
now given the surgeon to begin. No special 
apparatus is necessary, though there is a 
simple device available for use in intra­
venous anesthesia. This apparatus is de­
scribed by Jarman and Abel7, in The Lancet 
for March 4, 1936.
Dosage
The amount of Evipal necessary to pro­
duce surgical anesthesia varies with the 
individual. In our series the average dose 
per patient happened to be 1.875 Gm., the 
largest single dose being 4.7 Gm. The prime 
consideration here is, not the total amount, 
but rather the distribution of that amount. 
Our fractional doses are characterized by 
smallness and frequency rather than quan­
tity, ever bearing in mind the maintenance
of a constant level of anesthesia. In this 
connection I take the quality of the respira­
tion as my cardinal guide. Under Evipal 
anesthesia the respiration closely resembles 
deep physiologic sleep, with a gentle stertor 
of definite depth and rhythmicity. The 
minutest detectable deviation from an estab­
lished rhythm and depth is taken as a sign 
for either giving or withholding the anes­
thetic.
It is imperative to call attention at this 
point to the necessity of keeping the airway 
clear at all times. An obstruction may 
serve to disturb the depth and rhythm of 
respiration. It is good procedure to use a 
mechanical airway (Cornell’s), unless it 
causes gagging. Should postoperative rest­
lessness occur, morphine furnishes prompt 
relief (Maloney6).
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